KMDS
E-submission
Search
- Page Path
- HOME > Search
Original Article
- Increased Mortality in Young-Onset Parkinson’s Disease
- Eldbjørg Hustad, Tor Åge Myklebust, Sasha Gulati, Jan O. Aasly
- J Mov Disord. 2021;14(3):214-220. Published online July 29, 2021
- DOI: https://doi.org/10.14802/jmd.21029
- 26,896 View
- 354 Download
- 12 Web of Science
- 12 Crossref
-
Abstract
PDF - Objective
Few studies have followed Parkinson’s disease (PD) patients from the time of diagnosis to the date of death. This study compared mortality in the Trondheim PD cohort to the general population, investigated causes of death and analyzed the associations between mortality and age at disease onset (AAO) and cognitive decline defined as Montreal Cognitive Assessment (MoCA) score below 26.
Methods
The cohort was followed longitudinally from 1997. By the end of January 2020, 587 patients had died. Comparisons to the Norwegian population were performed by calculating standardized mortality ratios (SMRs). Survival curves were estimated using the standard Kaplan-Meier estimator, and multivariable Cox proportional hazard models were estimated to investigate associations.
Results
SMR was 2.28 [95% confidence interval (CI): 2.13–2.44] for the whole cohort. For participants with AAO 20–39 years, the SMR was 5.55 (95% CI: 3.38–8.61). Median survival was 15 years (95% CI: 14.2–15.5) for the whole cohort. Early-onset PD (EOPD) patients (AAO < 50 years) had the longest median survival time. For all groups, there was a significant shortening in median survival time and an almost 3-fold higher age- and sex-adjusted hazard ratio for death when the MoCA score decreased below 26.
Conclusion
PD patients with an AAO before 40 years had a more than fivefold higher mortality rate compared to a similar general population. EOPD patients had the longest median survival; however, their life expectancy was reduced to a greater degree than that of late-onset PD patients. Cognitive impairment was strongly associated with mortality in PD. -
Citations
Citations to this article as recorded by
- Levodopa–entacapone–carbidopa intestinal gel: Data from the Swedish national registry for Parkinson's disease
Mezin Öthman, Filip Bergquist, Per Odin, Monica Scharfenort, Anders Johansson, Ioanna Markaki, Per Svenningsson, Nil Dizdar, Dag Nyholm
European Journal of Neurology.2025;[Epub] CrossRef - Case‐Fatality Rate in Parkinson's Disease: A Nationwide Registry Study
Jussi O.T. Sipilä, Valtteri Kaasinen, Päivi Rautava, Ville Kytö
Movement Disorders Clinical Practice.2024; 11(2): 152. CrossRef - Genome-wide determinants of mortality and motor progression in Parkinson’s disease
Manuela M. X. Tan, Michael A. Lawton, Miriam I. Pollard, Emmeline Brown, Raquel Real, Alejandro Martinez Carrasco, Samir Bekadar, Edwin Jabbari, Regina H. Reynolds, Hirotaka Iwaki, Cornelis Blauwendraat, Sofia Kanavou, Leon Hubbard, Naveed Malek, Katherin
npj Parkinson's Disease.2024;[Epub] CrossRef - Empowering the management of early-onset Parkinson’s disease: The role of technology
Roongroj Bhidayasiri, Ornanong Udomsirithamrong, Adrian de Leon, Walter Maetzler, Andrea Pilotto
Parkinsonism & Related Disorders.2024; 129: 107052. CrossRef - Different neurotoxicity and seeding activity between α-synuclein oligomers formed in plasma of patients with Parkinson’s disease and multiple system atrophy
Hanjiang Luo, Xiaohan Yu, Pengjie Li, Junya Hu, Wei Li, Xin Li, Min Chen, Shun Yu
Neuroscience.2024; 557: 1. CrossRef - Tinetti balance performance is associated with mortality in older adults with late-onset Parkinson’s disease: a longitudinal study
Louise Laurent, Pierre Koskas, Janina Estrada, Mélanie Sebbagh, Sophie Lacaille, Agathe Raynaud-Simon, Matthieu Lilamand
BMC Geriatrics.2023;[Epub] CrossRef - Letter in response to Cole-Hunter et al., 2023: What does “Parkinson’s disease mortality” mean?
Isabell Katharina Rumrich, Valtteri Kaasinen, Otto Hänninen, Sirpa Hartikainen, Anna-Maija Tolppanen
Environment International.2023; 173: 107852. CrossRef - Differences in Survival across Monogenic Forms of Parkinson's Disease
Aymeric Lanore, Fanny Casse, Christelle Tesson, Thomas Courtin, Poornima Jayadev Menon, Sara Sambin, Graziella Mangone, Louise‐Laure Mariani, Suzanne Lesage, Alexis Brice, Alexis Elbaz, Jean‐Christophe Corvol
Annals of Neurology.2023; 94(1): 123. CrossRef - Real-World Prescription Patterns For Patients With Young-Onset Parkinson’s Disease in China: A Trend Analysis From 2014 to 2019
Xiao-qin Liu, Xiao-yu Wang, Hui-ming Shen, Wen-yuan Pang, Ming-kang Zhong, Chun-lai Ma
Frontiers in Pharmacology.2022;[Epub] CrossRef - Montreal cognitive assessment (MoCA) is highly correlated with 1-year mortality in hip fracture patients
R. M. Y. Wong, R. W. K. Ng, W. W. Chau, W. H. Liu, S. K. H. Chow, C. Y. Tso, N. Tang, W.-H. Cheung
Osteoporosis International.2022; 33(10): 2185. CrossRef - Obituary for Jan O. Aasly (1950–2022)
Matthew J. Farrer
Movement Disorders.2022; 37(9): 1783. CrossRef - Age Cutoff for Early‐Onset Parkinson's Disease: Recommendations from the International Parkinson and Movement Disorder Society Task Force on Early Onset Parkinson's Disease
Raja Mehanna, Katarzyna Smilowska, Jori Fleisher, Bart Post, Taku Hatano, Maria Elisa Pimentel Piemonte, Kishore Raj Kumar, Victor McConvey, Baorong Zhang, Eng‐King Tan, Rodolfo Savica
Movement Disorders Clinical Practice.2022; 9(7): 869. CrossRef
- Levodopa–entacapone–carbidopa intestinal gel: Data from the Swedish national registry for Parkinson's disease
First
Prev
